3
|
McCarthy NS, Vangjeli C, Surendran P, Treumann A, Rooney C, Ho E, Sever P, Thom S, Hughes AD, Munroe PB, Howard P, Johnson T, Caulfield M, Shields DC, O'Brien E, Fitzgerald DJ, Stanton AV. Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A 2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Atherosclerosis 2018; 269:42-49. [PMID: 29258006 PMCID: PMC5813793 DOI: 10.1016/j.atherosclerosis.2017.12.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 11/17/2017] [Accepted: 12/07/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND AND AIMS Elevated urinary 11-dehydro thromboxane B2 (TxB2), a measure of thromboxane A2 formation in vivo, predicts future atherothrombotic events. To further understand this relationship, the genetic determinants of 11-dehydro TxB2 and their associations with cardiovascular morbidity were investigated in this study. METHODS Genome-wide and targeted genetic association studies of urinary 11-dehydro TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants. RESULTS The strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 (rs10510230, rs4684343), these 5 single nucleotide polymorphisms (SNPs) were independently associated with 11-dehydro TxB2 formation. Haplotypes of 11-dehydro TxB2 increasing alleles for both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB2, explaining 5.2% and 4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, respectively. In a second ASCOT population (n = 6199), addition of these 5 SNPs significantly improved the covariate-only Cox proportional hazards model for cardiovascular events (chisq = 14.7, p=0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB2 were individually associated with greater incidences of cardiovascular events - rs10515638 (HR = 1.31, p=0.01) and rs10510230 (HR = 1.25, p=0.007); effect sizes were larger in those not taking aspirin. CONCLUSIONS PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making regarding the use of aspirin in primary prevention.
Collapse
Affiliation(s)
- Nina S McCarthy
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland; Centre for the Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia.
| | - Ciara Vangjeli
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland
| | - Praveen Surendran
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland; School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland
| | - Achim Treumann
- Newcastle University Protein and Proteome Analysis (NUPPA), University of Newcastle, Newcastle upon Tyne, UK
| | - Cathy Rooney
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland
| | - Emily Ho
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland
| | - Peter Sever
- International Centre for Circulatory Health, Imperial College London, London, UK
| | - Simon Thom
- International Centre for Circulatory Health, Imperial College London, London, UK
| | - Alun D Hughes
- International Centre for Circulatory Health, Imperial College London, London, UK
| | - Patricia B Munroe
- Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK
| | - Philip Howard
- Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK
| | - Toby Johnson
- Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
| | - Mark Caulfield
- Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK
| | - Denis C Shields
- School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland
| | - Eoin O'Brien
- School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland
| | - Desmond J Fitzgerald
- School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland
| | - Alice V Stanton
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland
| |
Collapse
|
5
|
McCarthy NS, Vangjeli C, Cavalleri GL, Delanty N, Shianna KV, Surendran P, O'Brien E, Munroe PB, Masca N, Tomaszewski M, Samani NJ, Stanton AV. Two further blood pressure loci identified in ion channel genes with a gene-centric approach. ACTA ACUST UNITED AC 2014; 7:873-9. [PMID: 25210050 DOI: 10.1161/circgenetics.113.000190] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND Blood pressure (BP) is highly heritable, but our understanding of the genetic causes underlying variations in BP is incomplete. In this study, we explored whether novel loci associated with BP could be identified using a genecentric approach in 3 community-based cohorts with accurate BP measurements. METHODS AND RESULTS Genotyping of 1857 single nucleotide polymorphisms (SNPs) in 91 ion channel genes was performed in a discovery cohort (n=358). Thirty-four SNPs associated with BP traits (P≤0.01) were followed up in an independent population (n=387); significant SNPs from this analysis were looked up in another independent population (n=1010) and meta-analyzed. Repeated clinic and ambulatory measurements were available for all but the discovery cohort (clinic only). Association analyses were performed, with systolic, diastolic, and pulse pressures as quantitative traits, adjusting for age and sex. Quantile-quantile plots indicated that the genecentric approach resulted in an inflation of association signals. Of the 29 SNPs taken forward from the discovery cohort, 2 SNPs were associated with BP phenotypes with the same direction of effect, with experiment-wide significance, in follow-up cohort I. These were rs2228291, in the chloride channel gene CLCN2, and rs10513488, in the potassium channel gene KCNAB1. Both associations were subsequently replicated in follow-up cohort II. CONCLUSIONS Using a genecentric design and 3 well-phenotyped populations, this study identified 2 previously unreported, biologically plausible, genetic associations with BP. These results suggest that dense genotyping of genes, in pathways known to influence BP, could add to candidate-gene and Genome Wide Association studies in further explaining BP heritability.
Collapse
Affiliation(s)
- Nina S McCarthy
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Ciara Vangjeli
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Gianpiero L Cavalleri
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Norman Delanty
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Kevin V Shianna
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Praveen Surendran
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Eoin O'Brien
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Patricia B Munroe
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Nicholas Masca
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Maciej Tomaszewski
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Nilesh J Samani
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.)
| | - Alice V Stanton
- From the Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland (N.S.M., C.V., G.L.C., N.D., P.S., A.V.S.); Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia (N.S.M.); Blood Pressure Unit and Department of Neurology, Beaumont Hospital, Beaumont, Dublin, Ireland (N.D., A.V.S.); Center for Human Genome Variation and Department of Medicine, Duke University School of Medicine, Durham, NC (K.V.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland (P.S., E.O.B.); Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, and Barts NIHR Biomedical Research Unit, London (P.B.M.); and Department of Cardiovascular Sciences, University of Leicester, and Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, United Kingdom (N.M., M.T., N.J.S.).
| |
Collapse
|
6
|
Wain LV, Sayers I, Soler Artigas M, Portelli MA, Zeggini E, Obeidat M, Sin DD, Bossé Y, Nickle D, Brandsma CA, Malarstig A, Vangjeli C, Jelinsky SA, John S, Kilty I, McKeever T, Shrine NRG, Cook JP, Patel S, Spector TD, Hollox EJ, Hall IP, Tobin MD. Whole exome re-sequencing implicates CCDC38 and cilia structure and function in resistance to smoking related airflow obstruction. PLoS Genet 2014; 10:e1004314. [PMID: 24786987 PMCID: PMC4006731 DOI: 10.1371/journal.pgen.1004314] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Accepted: 03/06/2014] [Indexed: 11/19/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity and mortality and, whilst smoking remains the single most important risk factor, COPD risk is heritable. Of 26 independent genomic regions showing association with lung function in genome-wide association studies, eleven have been reported to show association with airflow obstruction. Although the main risk factor for COPD is smoking, some individuals are observed to have a high forced expired volume in 1 second (FEV1) despite many years of heavy smoking. We hypothesised that these "resistant smokers" may harbour variants which protect against lung function decline caused by smoking and provide insight into the genetic determinants of lung health. We undertook whole exome re-sequencing of 100 heavy smokers who had healthy lung function given their age, sex, height and smoking history and applied three complementary approaches to explore the genetic architecture of smoking resistance. Firstly, we identified novel functional variants in the "resistant smokers" and looked for enrichment of these novel variants within biological pathways. Secondly, we undertook association testing of all exonic variants individually with two independent control sets. Thirdly, we undertook gene-based association testing of all exonic variants. Our strongest signal of association with smoking resistance for a non-synonymous SNP was for rs10859974 (P = 2.34 × 10(-4)) in CCDC38, a gene which has previously been reported to show association with FEV1/FVC, and we demonstrate moderate expression of CCDC38 in bronchial epithelial cells. We identified an enrichment of novel putatively functional variants in genes related to cilia structure and function in resistant smokers. Ciliary function abnormalities are known to be associated with both smoking and reduced mucociliary clearance in patients with COPD. We suggest that genetic influences on the development or function of cilia in the bronchial epithelium may affect growth of cilia or the extent of damage caused by tobacco smoke.
Collapse
Affiliation(s)
- Louise V. Wain
- University of Leicester, Department of Health Sciences, Leicester, United Kingdom
- * E-mail:
| | - Ian Sayers
- Division of Respiratory Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom
| | - María Soler Artigas
- University of Leicester, Department of Health Sciences, Leicester, United Kingdom
| | - Michael A. Portelli
- Division of Respiratory Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom
| | | | - Ma'en Obeidat
- University of British Columbia Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, Canada
| | - Don D. Sin
- University of British Columbia Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, Canada
| | - Yohan Bossé
- Institut universitaire de cardiologie et de pneumologie de Québec, Department of Molecular Medicine, Laval University, Québec, Canada
| | - David Nickle
- Merck Research Laboratories, Boston, Massachusetts, United States of America
- Merck, Rahway, New Jersey, United States of America
| | - Corry-Anke Brandsma
- University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, GRIAC Research Institute, Groningen, The Netherlands
| | | | | | - Scott A. Jelinsky
- Pfizer Worldwide R&D, Cambridge, Massachusetts, United States of America
| | - Sally John
- Pfizer Worldwide R&D, Cambridge, Massachusetts, United States of America
| | - Iain Kilty
- Pfizer Worldwide R&D, Cambridge, Massachusetts, United States of America
| | - Tricia McKeever
- School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom
| | - Nick R. G. Shrine
- University of Leicester, Department of Health Sciences, Leicester, United Kingdom
| | - James P. Cook
- University of Leicester, Department of Health Sciences, Leicester, United Kingdom
| | - Shrina Patel
- Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
| | - Tim D. Spector
- Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
| | - Edward J. Hollox
- University of Leicester, Department of Genetics, Leicester, United Kingdom
| | - Ian P. Hall
- Division of Respiratory Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom
| | - Martin D. Tobin
- University of Leicester, Department of Health Sciences, Leicester, United Kingdom
- National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom
| |
Collapse
|
9
|
Vangjeli C, Clarke N, Quinn U, Dicker P, Tighe O, Ho C, O'Brien E, Stanton AV. Confirmation That the Renin Gene Distal Enhancer Polymorphism
REN
-5312C/T Is Associated With Increased Blood Pressure. ACTA ACUST UNITED AC 2010; 3:53-9. [DOI: 10.1161/circgenetics.109.899930] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Background—
Studies of knockout and transgenic mice have demonstrated key roles for genes encoding components of the renin angiotensin system in blood pressure regulation. However, whether polymorphisms in these genes contribute to the cause of essential hypertension in humans is still a matter of debate.
Methods and Results—
We performed an experiment with dense tagging single-nucleotide polymorphism coverage of 4 genes encoding proteins that control the overall activity of the cascade, namely renin, angiotensinogen, angiotensin-converting enzyme, and angiotensin-converting enzyme 2, in 2 Irish populations. Both clinic and 24-hour ambulatory blood pressure measurements were available from population I (n=387), whereas just clinic blood pressure was measured in population II (n=1024). Of the 23 polymorphisms genotyped, only a single renin gene polymorphism, REN-5312C/T, showed consistent statistically significant associations with elevated diastolic pressures. Carriage of one REN-5312T allele was associated with the following age- and sex-adjusted increments in diastolic pressures (mean [95% CI]): population I, clinic, 1.5 mm Hg (0.3 to 2.8); daytime, 1.4 mm Hg (0.4 to 2.4); night-time, 1.3 mm Hg (0.4 to 2.3), and population II, clinic, 1.1 mm Hg (0.1 to 2.1). Haplotypic analyses and multivariate stepwise regression analyses were in concordance with individual single-nucleotide polymorphism analyses.
Conclusions—
The REN-5312T allele had been shown previously to result in increased in vitro expression of the renin gene. We have now shown, in 2 independent populations, that carriage of a REN-5312T allele is associated with elevated diastolic blood pressure. These data provide evidence that renin is an important susceptibility gene for arterial hypertension in whites.
Collapse
Affiliation(s)
- Ciara Vangjeli
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Niamh Clarke
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Ursula Quinn
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Patrick Dicker
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Orna Tighe
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Clara Ho
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Eoin O'Brien
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| | - Alice V. Stanton
- From the Molecular and Cellular Therapeutics (C.V., N.C., U.Q., O.T., C.H., A.S.), Royal College of Surgeons in Ireland; Division of Population Health Sciences (P.D.), Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland; and the Conway Institute of Biomolecular and Biomedical Research (E.B.), University College Dublin, Belfield, Dublin, Ireland
| |
Collapse
|